<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157233">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052779</url>
  </required_header>
  <id_info>
    <org_study_id>FER-CKD-201</org_study_id>
    <nct_id>NCT01052779</nct_id>
  </id_info>
  <brief_title>Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease</brief_title>
  <acronym>FIRST</acronym>
  <official_title>Ferumoxytol Compared to Iron Sucrose Trial (FIRST): A Randomized, Multicenter, Trial of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of intravenous (IV)
      ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA) in
      subjects with chronic kidney disease (CKD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of IV ferumoxytol compared to IV iron sucrose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of ferumoxytol as compared to iron sucrose by assessing changes in hemoglobin from Baseline to Week 5</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Iron Deficiency</condition>
  <condition>Anemia</condition>
  <condition>Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Iron Sucrose Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Safety and efficacy of IV iron sucrose for the treatment of iron deficiency anemia (IDA) in subjects with chronic kidney disease (CKD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferumoxytol arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Safety and efficacy of intravenous (IV) ferumoxytol for the treatment of iron deficiency anemia (IDA) in subjects with chronic kidney disease (CKD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferumoxytol</intervention_name>
    <description>IV injection of ferumoxytol for a total cumulative dose of 1.02 g</description>
    <arm_group_label>Ferumoxytol arm</arm_group_label>
    <other_name>Feraheme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iron sucrose</intervention_name>
    <description>IV infusion of iron sucrose for a total cumulative dose of 1.0 g</description>
    <arm_group_label>Iron Sucrose Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Key Inclusion Criteria include:

          1. Males and females ≥18 years of age

          2. An eGFR &lt;60 mL/min or a diagnosis of CKD (eg, nephropathy, nephritis)

          3. Hemoglobin &lt;11.0 g/dL

          4. TSAT &lt;30%

          5. Hemodialysis subjects on maintenance dialysis for at least three months prior to
             screening and currently receiving dialysis three times per week

          6. Female subjects of childbearing potential who are sexually active must be on an
             effective method of birth control for at least 1 month prior to screening and agree
             to remain on birth control until completion of the study

        Exclusion Criteria:

        Key Exclusion Criteria include:

          1. History of allergy to IV iron

          2. Allergy to 2 or more classes of drugs

          3. Female subjects who are pregnant or intend to become pregnant, breastfeeding, within
             3 months postpartum, or have a positive serum or urine pregnancy test

          4. Hemoglobin ≤7.0 g/dL

          5. Received another investigational agent within 4 weeks prior to screening, or planned
             receipt of an investigational agent not specified by this protocol during the study
             period

          6. Known causes of anemia other than iron deficiency (eg, hemolysis, vitamin B12 or
             folate deficiency, etc)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Strauss, MD, FACC</last_name>
    <role>Study Director</role>
    <affiliation>AMAG Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMAG Pharmaceuticals, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 29, 2013</lastchanged_date>
  <firstreceived_date>January 15, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>April 3, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron deficiency anemia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>Feraheme</keyword>
  <keyword>ferumoxytol</keyword>
  <keyword>iron sucrose</keyword>
  <keyword>iron deficiency anemia (IDA)</keyword>
  <keyword>chronic kidney disease (CKD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferrosoferric Oxide</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
